Onconetix Valuation
| ONCO Stock | USD 0.13 0.04 23.53% |
Onconetix seems to be undervalued based on Macroaxis valuation methodology. Our model determines the value of Onconetix from analyzing the company fundamentals such as Return On Equity of -2.01, current valuation of 11.64 M, and Shares Owned By Insiders of 35.47 % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Onconetix's price fluctuation is extremely dangerous at this time. Calculation of the real value of Onconetix is based on 3 months time horizon. Increasing Onconetix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Onconetix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Onconetix Stock. However, Onconetix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.13 | Real 2.35 | Hype 0.1 | Naive 0.15 |
The intrinsic value of Onconetix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Onconetix's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Onconetix helps investors to forecast how Onconetix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Onconetix more accurately as focusing exclusively on Onconetix's fundamentals will not take into account other important factors: Onconetix Total Value Analysis
Onconetix is now forecasted to have valuation of 11.64 M with market capitalization of 1.86 M, debt of 9.89 M, and cash on hands of 113.36 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Onconetix fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
11.64 M | 1.86 M | 9.89 M | 113.36 K |
Onconetix Investor Information
About 35.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.05. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Onconetix recorded a loss per share of 87.25. The entity had not issued any dividends in recent years. The firm had 1:40 split on the 24th of September 2024. Based on the key measurements obtained from Onconetix's financial statements, Onconetix is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Onconetix Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Onconetix has an asset utilization ratio of 0.0668 percent. This suggests that the Company is making $6.68E-4 for each dollar of assets. An increasing asset utilization means that Onconetix is more efficient with each dollar of assets it utilizes for everyday operations.Onconetix Ownership Allocation
Onconetix has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Onconetix Profitability Analysis
The company reported the previous year's revenue of 58.47 K. Net Loss for the year was (37.41 M) with loss before overhead, payroll, taxes, and interest of (732.03 K).About Onconetix Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Onconetix. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Onconetix based exclusively on its fundamental and basic technical indicators. By analyzing Onconetix's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Onconetix's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Onconetix. We calculate exposure to Onconetix's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Onconetix's related companies.Onconetix Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 17.1 M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Onconetix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.